Australia: Applications For Preliminary Discovery Are Not Dress Rehearsals Or "Mini Trials"

Last Updated: 1 May 2018
Article by Paul Dewar

Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCAFC 193

On 29 November 2017, the Full Court of the Federal Court of Australia upheld an appeal from the primary judge in respect of orders made refusing an application for preliminary discovery pursuant to r 7.23 of the Federal Court Rules 2011 (Cth) (FCRs). The three separate judgments of Chief Justice Allsop and Justices Perram and Nicholas contain a comprehensive analysis of FCR 7.23 and the prior case law, thereby providing a detailed and practical guide for prospective litigants seeking to determine whether they may have the right to obtain preliminary discovery.

Setting the scene

Pfizer manufactures etanercept which is the active ingredient in ENBREL, a biological medicine used in the treatment of autoimmune diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis and psoriatic arthritis. Since 2003, Pfizer has been the sponsor of ENBREL on the Australian Register of Therapeutic Goods (ARTG). Until July 2016, ENBREL was the only product containing etanercept registered on the ARTG. Samsung Bioepis AU (SBA) is the sponsor of two pharmaceuticals products containing etanercept as the active ingredient registered on the ARTG under the name BRENZYS from July 2016.

Pfizer's preliminary discovery application

Pfizer made an application for preliminary discovery in order to obtain certain confidential documents SBA had lodged with the Therapeutic Goods Administration, which Pfizer believed would assist it in determining whether or not to commence proceedings against SBA for patent infringement.

Decision at first instance

In Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCA 285, the central issue at first instance was whether Pfizer had satisfied FCR 7.23(1)(a) which required Pfizer to demonstrate that it held a reasonable belief that it may have the right to obtain relief from SBA for infringement of three of its process patents.

That belief was expressed by a representative of Pfizer, and was based on the expert evidence of Pfizer's expert, Dr Ibarra. Dr Ibarra's evidence was to the effect that, in her opinion and based on her expertise, the close similarity of the glycosylation profiles of the two products was a basis to believe the upstream process to make BRENZYS was similar to that of Pfizer's process patents.

It was accepted by the primary judge that based on Dr Ibarra's evidence Pfizer subjectively believed that it may have a right to relief. However, his Honour held that irrespective of Pfizer's subjective belief, the evidence of Dr Ibarra, when considered against the evidence of SBA's experts, objectively supported no more than a "mere suspicion" that SBA infringed its process patents. In the result, his Honour held that Pfizer had failed to demonstrate a reasonable belief that it may have the right to obtain relief for patent infringement from SBA.

Furthermore, the primary judge held that even if Pfizer had established it held a reasonable belief, he would have exercised his discretion against granting the preliminary discovery order sought. His Honour held that whilst asking the Court to exercise its coercive powers to require SBA to expose its confidential process documents for the purpose of commencing proceedings, Pfizer failed to provide the Court with the basis upon which it may be discerned including whether the Pfizer process itself falls within any of the claims. This proposition was foundational to the chain of inferences which Pfizer propounded the Court ought to draw. His Honour held that whilst Pfizer's expert evidence was admissible, its utility in assessing the strength of the inferences Pfizer asked to have drawn in its favour was weakened considerably by the absence of detail from which the inferences may be drawn.

The correct approach to determining "reasonable belief" became the central issue on appeal.

On appeal

The Full Court held that the relevant test under the rule is that preliminary discovery will be granted where a prospective applicant subjectively believes it may have a right to obtain relief and that belief is reasonably open on the evidence (i.e. not unreasonable, untenable, irrational or baseless).

To succeed, SBA would have had to demonstrate that no reasonable person apprised of Dr Ibarra's evidence would think that a right to obtain relief may exist. The Full Court found that Dr Ibarra's views were capable of providing a reasonable basis for Pfizer's subjective belief even though those views were contested by SBA. The correct question was not which witness was more persuasive or to be preferred, but whether Dr Ibarra's views so lacked foundation that it was not open to Pfizer to rely upon them.

The Full Court held that confusion had arisen out of previous authorities where the Court had occasionally applied a standard of the existence of a right to relief rather than the possible existence of a right to relief. This, the Court held, had led to a tendency of such applications to become "mini-trials" because of a misapprehension that a prospective applicant must show the reasonableness of a right to relief existing rather than possibly existing.

In this regard, the Full Court found that whilst Dr Ibarra may be wrong, her views could not be put to one side as unreasonable or untenable in the kind of hearing anticipated for the operation of the rule and her views were not ones that were unreasonably held. Accordingly, Pfizer's belief based upon Dr Ibarra's evidence was reasonable and satisfied FCR 7.23(1)(a). In making their observations, the Court reiterated that proceedings of an interlocutory nature are not generally the appropriate forum for final findings of fact to be made, especially in light of contested scientific evidence and absent cross examination.

What does this mean for prospective applicants?

The forming of a reasonable belief by a prospective applicant will necessarily involve some degree of speculation; the relevant inquiry is whether the belief arising from the speculation is a reasonable one. The Full Court's decision makes it easier to meet that standard and reiterates the importance of giving the FCRs the meaning that the words intend.

The Full Court's decision means that applications for preliminary discovery should be less complex and cheaper to obtain and there will be a movement away from the tendency toward the extensive "mini trials" that have occurred in recent years.

Expert evidence can be relied upon by the relevant decision maker to establish belief in circumstances where the expert opinion discloses familiarity with the relevant material (in this case the patents and Pfizer's manufacturing processes) and necessary qualifications, technical knowledge and experience.

In practice, to defeat a claim for preliminary discovery it will be necessary either to show that the subjectively held belief does not exist or, if it does, that there is no reasonable basis for the belief. Showing that some aspect of the material on which the belief is based is contestable, or even arguably wrong, will rarely make good such a contention.

Take away points

  • The plain words of the rule must be firmly kept in mind and not be supplanted for other less precise words or phrases – all that is required is that the prospective applicant reasonably believes he or she may have a right to obtain relief.
  • The current iteration of the rule was not intended to disturb the settled principles governing the application of the former rule, O 15A, r 6.
  • Interlocutory applications are not the appropriate place for the making of final determinations on contested evidence, especially in circumstances where there is no cross examination and the evidence cannot be tested.
  • An applicant's reasonable belief need only be founded on considerations or views that are reasonably open or arguable.
  • To defeat a claim for preliminary discovery it will be necessary to demonstrate that the subjectively held belief either does not exist or that there is no reasonable basis for the belief.

This decision is still subject to an appeal period and therefore there may be more acts to follow.

18 December, 2017

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions